International AIDS Society

IAS TB/HIV Research Prize

To contribute to generating interest and stimulating research on basic, clinical and operational research in TB/HIV prevention, care and treatment, the IAS TB/HIV Research Prize was first awarded in 2009 at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town.

The US$2,000 IAS TB/HIV Research Prize in an incentive for young and established researchers to investigate pertinent research questions that affect TB/HIV co-infection and operational effectiveness of implementing core TB/HIV collaborative services.

To be eligible for the prize, abstracts submitted to AIDS 2014 must meet the following criteria:
  • The abstract must have been accepted as an oral presentation, poster discussion or poster exhibition by the Scientific Programme Committee
  • Research must be related to HIV and TB


All abstract submitters who meet the criteria are automatically considered.

Previous Prize Winners

2013 IAS TB/HIV Research Prize

James Houston, United States, for the abstract, Tuberculosis burden is a barrier to starting isoniazid preventive therapy in HIV-infected children enrolled in care.

2012 IAS TB/HIV Research Prize

Jonathan Golub, USA, for the abstract, “The TB/HIV in Rio de Janeiro (THRio) study: a step-wedged cluster randomized trial measuring the impact of tuberculosis (TB) screening and isoniazid preventive therapy (IPT) on incidence of TB and death”.

2011 IAS TB/HIV Research Prize

Sabine Margot Hermans, The Netherlands, for her abstract, “Integration of HIV and TB services results in earlier and more prioritised ART initiation in Uganda”.

2010 IAS TB/HIV Research Prize

Katherine Todrys, UK, for her abstract, “HIV and TB management in six Zambian prisons demonstrate improved but ongoing prevention, testing and treatment gaps”.

2009 IAS TB/HIV Research Prize

Clare van Halsema, UK, for her abstract, “Good tuberculosis treatment outcomes and no evidence of increased drug resistance in individuals previously exposed to isoniazid preventive therapy in a population with high HIV prevalence”.